



Healthcare Council Structure

June 2009

Healthcare Council Structure

Work Areas

Horizontal issues

Implementation-related issues

J. Vanhemelryck (BIO.be) TBC

SMEs-related issues

J. Wildy (BIA)

Impact of the financial crisis

TBC

Value of biotech Innovation
Champion: A. Rappagliosi (GSK)

Emerging Technologies
Champion: D. Niese (Novartis)

Specialised Areas
Champion: E. Tambuyzer (Genzyme)

Biotech Challenges
Champion: T. Bols (MerckSerono)

Patient Advisory Group
HC Council Chair

Cross-Border Healthcare
(all but art. 17)
P. Spindler (Dansk Biotek)

Joint Rare Diseases and Orphan Medicines TF
E Tambuyzer (Genzyme)

Biosimilars
T. Bols (MerckSerono)

Value of Innovation in Health Policy
J. Anderson (GSK)

Animal Testing Directive
K Blumer (Novartis)

Economic Contribution of OMPs to society
TBC

Purchasing & Tendering practices
P. Morgese (Merck Serono)

Health Technology Assessment (HTA)
R. Jensen (Novo Nordisk)

Advanced Therapies
W. Hughes-Wilson (Genzyme)

Personalised medicines & Genetic testing
T Kievits (Pamgene)

Additional Indications / data exclusivity
M. Schmiegelow (Novo Nordisk)

Pharma Package
J. Jenewein (Amgen)

Nano-medicines
D. Niese (Novartis)

Impact of financial crisis on ODs
TBC

Clinical Trials
C. Abouzeid (BIA)